Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 19/20 | 0.42 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5225571 | 0.91 | TACR1 (0.40) | TACR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5226991 | 0.90 | TACR1 (0.40) | TACR1 | |
| SCHEMBL5225834 | 0.89 | TACR1 (0.44) | TACR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5232458 | 0.89 | TACR1 (0.40) | TACR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5232740 | 0.88 | TACR1 (0.42) | TACR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5232346 | 0.88 | TACR1 (0.42) | TACR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5230354 | 0.88 | SMO (0.40) | TACR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5226749 | 0.88 | TACR1 (0.37) | TACR1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5231577 | 0.88 | TACR1 (0.39) | TACR1 | |
| SCHEMBL5228816 | 0.88 | TACR1 (0.40) | TACR1PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1496059-B1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES | KYORIN SEIYAKU KK (JP) | 2007-08-15 | — | — | EP | disclosed |
| US-7064119-B2 | Fused bicyclic pyrimidine derivatives | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2006-06-20 | — | — | US | disclosed |
| US-20050159409-A1 | Fused bicyclic pyrimidine derivatives | KYORIN PHARMACEUTICAL CO. LTD. (JP) | 2005-07-21 | — | — | US | disclosed |
| EP-1496059-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES | Kyorin Pharmaceutical Co., Ltd. (JP) | 2005-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159409-A1 | Fused bicyclic pyrimidine derivatives | BDKRB1, BDKRB2, TACR1 | TACR1 3/4885PSEN1 4147/4885PSEN2 4165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.